Compare BORR & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BORR | TYRA |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2017 | 2021 |
| Metric | BORR | TYRA |
|---|---|---|
| Price | $4.51 | $31.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $6.25 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 6.9M | 1.0M |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.80 | N/A |
| Revenue Next Year | $21.67 | N/A |
| P/E Ratio | $20.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.85 | $9.96 |
| 52 Week High | $6.66 | $40.65 |
| Indicator | BORR | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.00 | 56.16 |
| Support Level | $3.95 | $30.10 |
| Resistance Level | $4.55 | $33.99 |
| Average True Range (ATR) | 0.19 | 1.83 |
| MACD | 0.07 | 0.42 |
| Stochastic Oscillator | 73.77 | 81.38 |
Borr Drilling Ltd is an offshore shallow-water drilling contractor providing services to the oil and gas industry. Its operations focus on the ownership, contracting, and operation of jack-up rigs in shallow-water areas, including the provision of related equipment and work crews to conduct oil and gas drilling and workover operations for exploration and production (E&P) customers. The company contracts its rigs on a dayrate basis to drill wells for integrated oil companies, state-owned national oil companies, and independent oil and gas companies. It operates in one reportable segment.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.